








key: cord-341101-5yvjbr5q
authors: Hashem, Anwar M.; Alghamdi, Badrah S.; Algaissi, Abdullah A.; Alshehri, Fahad S.; Bukhari, Abdullah; Alfaleh, Mohamed A.; Memish, Ziad A.
title: Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review
date: 2020-05-06
journal: Travel Med Infect Dis
DOI: 10.1016/j.tmaid.2020.101735
sha: 
doc_id: 341101
cord_uid: 5yvjbr5q

The rapidly spreading Coronavirus Disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), represents an unprecedented serious challenge to the global public health community. The extremely rapid international spread of the disease with significant morbidity and mortality made finding possible therapeutic interventions a global priority. While approved specific antiviral drugs against SARS-CoV-2 are still lacking, a large number of existing drugs are being explored as a possible treatment for COVID-19 infected patients. Recent publications have re-examined the use of Chloroquine (CQ) and/or Hydroxychloroquine (HCQ) as a potential therapeutic option for these patients. In an attempt to explore the evidence that supports their use in COVID-19 patients, we comprehensively reviewed the previous studies which used CQ or HCQ as an antiviral treatment. Both CQ and HCQ demonstrated promising in vitro results, however, such data have not yet been translated into meaningful in vivo studies. While few clinical trials have suggested some beneficial effects of CQ and HCQ in COVID-19 patients, most of the reported data are still preliminary. Given the current uncertainty, it is worth being mindful of the potential risks and strictly rational the use of these drugs in COVID-19 patients until further high quality randomized clinical trials are available to clarify their role in the treatment or prevention of COVID-19.

6 a receptor for cell entry, suggesting a possible similar effect of CQ on SARS-CoV-2 at this step of virus replication [40] . CQ can also affect early stage of virus replication by inhibiting virus-endosome fusion, likely via increasing endosomal pH [41] . CoVs such as SARS-CoV were shown to be able to enter target cells via pH-dependent mechanism in which the acidic pH of the lysosome triggers fusion of the viral and endosomal membranes resulting in viral particle uncoating and subsequent release of viral nucleic acid into the cytoplasm [42] . CQ can also impair posttranslational modifications of viral proteins through interfering with proteolytic processes [43] and inhibition of glycosylation via specific interactions with sugarmodifying enzymes or glycosyltransferases [28] . CQ can also hamper lysosomal protein degradation and lysosomal fusion with autophagosomes [44] [45] [46] . Moreover, it has been suggested that CQ has the ability to affect the cytotoxic mechanisms and works as antiautophagy agent in vitro [47] . CQ works as anti-inflammatory agent through reducing tumor necrosis factor (TNFα) release and suppressing TNF receptors on monocytes [26, 28] .

On the other hand, HCQ has a similar effect to CQ in interfering with the glycosylation of ACE2, blocking virus/cell fusion and inhibiting lysosomal activity by increasing pH [22] . HCQ can also impede major histocompatibility complex (MCH) class II expression which inhibits T cell activation, expression of CD145 and cytokines release [48] [49] [50] . Furthermore, HCQ has been shown to impair Toll-like receptors (TLRs) signaling through increasing endosomal pH and interfering with TLR7 and TLR9 binding to their DNA/RNA ligands thereby inhibiting transcription of pro-inflammatory genes [51] [52] [53] . The aforementioned immunomodulatory properties of CQ and HCQ have raised the interest in using these drugs in COVID-19 patients at risk of cytokines release syndrome (CRS) [22] . 7 

The fact that both CQ and HCQ are considered for the management of COVID-19 patients clearly highlights the need to better understand their pharmacokinetics (PK) parameters.

However, a full understanding of these parameters has been challenging despite the numerous reported studies. Generally, PK parameters for CQ and HCQ are comparable (Table 1) [54, 55] . Following oral administration of CQ and HCQ, their bioavailability can reach up to 80% with plasma peak time around 2-4 hours [56] [57] [58] . Thus, parenteral administration, if available, might be a better route especially that oral administration has shown huge interpatient variability [56, 59, 60] . The long half-life of both CQ and HCQ which could range from 30 to 60 days is likely attributed to their large volume of distribution (200 to 800 L/kg) and extensive tissue uptake [61] [62] [63] [64] [65] [66] [67] [68] . CQ and HCQ are metabolized via CYP-450 enzymes to other active compounds, which are responsible for the extended pharmacological actions and increased toxicity [61, 69] . Up to 60% of CQ and HCQ is primarily excreted renally as unchanged or metabolized forms, and the remaining (40%) is usually cleared through the liver, feces and skin or stored in other lean body tissues [54, [69] [70] [71] [72] [73] [74] . It's important to note that CQ and HCQ have a chiral center, which produces two enantiomers R(−) or S(+) forms or isomers [75] , in which little is known about the differences in their pharmacological activity and their corresponding metabolites. Most clinically used CQ and HCQ exist as a racemic mixture (50:50) of both isomers which complicates the understanding of their PK and associated toxicity as they could behave differently inside the body [57, [75] [76] [77] .

The most common CQ and HCQ adverse effects are gastrointestinal symptoms such as nausea, vomiting and abdominal discomfort [78] , and uncommonly worrisome fulminant hepatic failure [79] , toxic epidermal necrolysis (TEN) [80] and cardiotoxicity that could 8 manifest with QT abnormality [81] [82] [83] . Nevertheless, over the years CQ and HCQ have maintained a good safety profile when used in several chronic diseases such as RA and SLE.

Despite some animal experiments suggesting that HCQ is probably less toxic than CQ, there is a lack of high quality evidence from clinical trials supporting this claim [74, [84] [85] [86] [87] . These toxicities could be related to the very long half-life and the large volume of distribution of both drugs. One of the significant toxic effects of CQ and HCQ is the possible ocular pigmentation due to their binding to melanin, which could lead to damage in different parts of the eye including the cornea, ciliary body and retina [88] . Notably, the incidence of such ocular toxicity is usually rare. For instance, it was shown that only 0.5% out of ~400 patients treated with HCQ (≤6.5 mg/kg/day) for 6 years due to RA or SLE had developed ocular related complications [89] . Most studies have shown that such complications might only occur with long term treatment of chronic diseases which extends for more than 5 years with doses above or equal to 6.5 mg/kg/day [90, 91] . However, ocular toxicity and changes could still occur with shorter treatments. Other complications such as development of proximal myopathy associated with respiratory failure have also been reported in patients treated with either CQ or HCQ [92] [93] [94] [95] . Nonetheless, most of these complications were seen in elderly patients with an average age of 70 years suffering from chronic RA or autoimmune diseases.

Both CQ and HCQ were also shown to be associated with rare but life-threatening cardiomyopathy [96] [97] [98] . Other less reported CQ and HCQ toxicities include urticaria [99] , ototoxicity [100, 101] and some neurological effects [102, 103] .

The antiviral effects of CQ were suggested at least 50 years ago [23, 25] . Since then, several studies have tested the ability of CQ and HCQ to inhibit the replication of a wide range of CoVs and non-CoV viruses in vitro as shown in Tables 2 and 3 , respectively. The majority of 9 these studies have revealed a substantial ability of CQ and HCQ as well as some of their derivatives to inhibit viral replication with no to low toxicity. Specifically, CQ has been shown to inhibit the replication of different CoVs including SARS-CoV, MERS-CoV and SARS-CoV-2 among others in several studies (Table 2) [37, [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] . Only two studies showed no significant inhibitory effects of CQ on MERS-CoV and mouse hepatitis virus (MHV4) [116, 117] . Other CQ derivatives such as amodiaquine (AMD), Ferroquine (FQ), Hydroxy ferroquine (HFQ) have been also shown to exerts some antiviral activity [105, 106] .

Interestingly enough, while HCQ does not seem to have a significant effect in reducing SARS-CoV and Feline CoV replication [106] , it was recently shown to have a potent in vitro inhibitory effect against SARS-CoV-2 replication [112, 116] .

Similarly, these compounds have shown excellent in vitro antiviral activity against several non CoV (mostly RNA viruses) with low toxicity in most cases (Table 3) . For instance, HIV was shown to be inhibited by CQ alone or in combination with HCQ, hydroxyurea (HU1), didanosine (ddI), zidovudine (ZDV), indinavir (IDV), saquinavir (SQV) or ritonavir (RTV) [106, [118] [119] [120] [121] [122] . While other derivatives such as HCQ and HFQ have been also shown to inhibit HIV replication [106, 123, 124] , one study showed no effect of HCQ and FQ on HIV [106] . Similarly, it was found that CQ could enhance Epstein-Barr virus replication [125] .

Furthermore, another study has suggested possible enhanced HIV replication with CQ treatment through protection of tat protein from proteolytic degradation [126] . Influenza A and B viruses have also been shown to be inhibited by CQ [27, [127] [128] [129] [130] [131] although contradicting results have been seen for some subtypes and strains such as avian H7N3 strains (A/Mallard/It/43/01 and A/Ty/It/220158/02) [106, 130] . Several other studies have also reported in vitro inhibitory effect of CQ on multiple viruses such as chikungunya virus (CHIKV) [41, 132, 133] , zika virus (ZIKV) [134] [135] [136] , Ebola virus (EBOV) [137] [138] [139] , dengue viruses (DENV) in mammalian cells [43, 140, 141] but not insect cells [141] as well 10 as several others [43, 139, [142] [143] [144] [145] [146] [147] [148] [149] [150] . Nonetheless, some reports failed to observe antiviral activity of CQ, HCQ and FQ on several other viruses including polio virus, reovirus, respiratory syncytial virus (RSV), herpes simplex viruses, coxsackie virus, vesicular stomatitis virus (VSV), vaccinia virus, sindbis virus, parainfluenza-3 virus and Punta Toro virus [106, 151] .

There are limited studies established to investigate the possible antiviral effect of CQ or HCQ in animal models (Table 4 ). In general, studies showed no significant effect of CQ on CoVs including SARS-CoV and feline infectious peritonitis virus (FIPV) replication or clinical scores in mice and cats, respectively [105, 110] . However, it has been found that CQ significantly reduced HCoV-OC43 dissemination and replication in mice central nervous system (CNS) after CQ administration [152] and increased the survival rate of HCoV-OC43 infected newborn mice when their mothers treated by CQ most probably through placental and maternal milk transfer [108] .

On the other hand, CQ administration has shown contradicting outcomes when used against non-CoVs RNA viruses in different animal models. Some studies have demonstrated antiviral efficacy of CQ in influenza A virus H5N1, ZIKV and EBOV infected mice [29, 134, 139] .

Interestingly, CQ was effective against ZIKV in both wild type and IFNAR deficient mice, and protected infected suckling pups from infection and microcephaly when given to their mothers [29, 134, 136] . However, several other studies showed no significant antiviral effect of CQ against influenza A H1N1 and H3N2 viruses in mice and Ferrets, respectively [129] .

Similarly, CQ was ineffective against EBOV in guinea pigs, mice and hamsters [137, 138] , Nipah virus (NiV) in Ferrets and hamsters [148, 153] , Hendra virus (HeV) in hamsters [148] , 11 CHIKV in cynomolgus macaques [133] , Lassa virus (LASV) in mice [139] and Semliki Forest Virus (SIV) in mice [154] . Importantly, most of these previous in vivo studies showed toxicity in animals [129, 133, 137, 138, 154] . Furthermore, it was shown that CQ could lead to disease exacerbation correlating with increased type I IFN response and delayed immune responses in CHIKV infected macaques [133] , increased mortality rate of SFV-infected mice [154] and NiV or HeV infected hamsters [148] .

There are very limited published clinical trials that studied the possible antiviral effect of CQ or HCQ in CoV and non-CoV infected patients (Table 5 ). These published clinical trials have clearly shown no significant benefit of using CQ in the prevention or treatment against influenza, DENV or CHIKV infections in patients [133, [155] [156] [157] [158] . In fact, in one study, patients treated with CQ were more likely to develop adverse effects such as arthralgia at day 200 post-treatment [157] . On the other hand, few studies have reported that HCQ could decease HIV-1 viremia, stabilize CD4 T cell count and reduce IL-6 and IgG levels in infected patients [159] , although others showed contradicting finding of increased HIV RNAemia in HCQ treated patients [160, 161] . Interestingly, while few clinical studies have suggested that the use of HCQ alone or with azithromycin (AZT) could be beneficial for COVID-19 patients as it reduces viral shedding and time to clinical recovery [162] [163] [164] , others have reported no effect in infected patients [165, 166] . However, it is important to note that most of these studies have several limitations in study designs with small sample sizes. Nonetheless, around 104 clinical trials are ongoing in different countries to asses and evaluate the therapeutic and prophylactic effects of both CQ and/or HCQ in COVID-19 patients (Table 6 ).

The COVID-19 pandemic has spread out of control and has caused considerable morbidity and mortality in several countries. In this unprecedented situation, clinicians have tried all kinds of treatments in an effort to stem the progression of this disease. One treatment that has received huge attention was the empirical use of anti-malarial CQ/HCQ. While there is no strong and enough scientific and clinical data to support their use, several countries have already included CQ/HCQ in COVID-19 treatment protocols [167, 168] , not only as a treatment option for severely ill patients but also as a prophylactic measure.

In this comprehensive review of the antiviral effects of CQ and HCQ on SARS-CoV-2 as well as other viruses, we show a broad variation in the research outcomes. Both CQ and HCQ demonstrated promising in vitro results, however, such data have not yet been translated into meaningful in vivo studies. While few clinical trials have suggested some beneficial effects of CQ and HCQ in COVID-19 patients, most of the reported data are still preliminary [20, 162] , [163] . Furthermore, at least 7 of the ongoing trials were canceled or stopped and it is not yet clear if this was due to possible adverse effects, ineffectiveness or other reasons.

There are several toxicities associated with these drugs [78] [79] [80] , the one that is foremost concerning is the possibility of QT prolongation and the risk of Torsades de pointes, which is a potentially life-threatening arrhythmia [81] [82] [83] . Nevertheless, while our literature review showed that this is quite rare, it is not yet evident whether there would be any additive or possible synergistic risk when these drugs are combined with other medications such as AZT [83] . In fact, it is challenging to base a treatment decision in the absence of a complete research cycle and a clear vision of drug efficacy and safety. Given the current uncertainty, it is worth being mindful of the potential risks and strictly rational the use of these drugs in 13 COVID-19 patients until further high quality randomized clinical trials are available to clarify their role in the treatment or prevention of COVID-19.

This work was funded by King Abdulaziz City for Science and Technology (KACST) grant number 09-1, which is a part of the Targeted Research Program (TRP). 

AZT: Azithromycin; Vit C: Vitamin C; Vit D: Vitamin D; LST: Losartan; RDV: Remdesivir; IFß-1a: Interferon ß-1a; NIVO: Nivolumab; TCZ: Tocilizumab; LEV: Levamisole; BUD: Budesonide; FORM: Formoterol; SOF: Sofosbuvir; LDV: Ledipasvir; OTV: Oseltamivir; ATV: Atazanavir; COBI: Cobicistat; TDF: Tenofovir disoproxil fumarate

HRCT: Pulmonary inflammation resolution time, IMV: invasive mechanical ventilation; HCW: Healthcare workers; ; ARS: Acute respiratory syndrome

SpO2/FiO2: oxygen saturation/fraction of inspired oxygen ratio

ICU: Intensive Care Unit; CRP: C-reactive protein

* The same study was registered in ISRCTN registry (registration no. ISRCTN50189673) with a total number of 5000 patients

); the European Union

ISRCTN registry

/) and the Australian New Zealand Clinical trial Registry (ANZCTR)

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics

Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group

Coronaviruses post-SARS: update on replication and pathogenesis

Bats are natural reservoirs of SARSlike coronaviruses

Detection and prevalence patterns of group I coronaviruses in bats, northern Germany

Further observations on the use of organ cultures in the study of acute respiratory-tract infections

A new virus isolated from the human respiratory tract

Identification of a new human coronavirus

Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia

Coronavirus as a possible cause of severe acute respiratory syndrome

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Koch's postulates fulfilled for SARS virus

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

A Novel Coronavirus from Patients with Pneumonia in China

Severe acute respiratory syndrome-related coronavirus: The species and its viruses -a statement of the Coronavirus Study Group

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression

Comparison of the antiviral activity in vitro of some non-steroidal antiinflammatory drugs

Antihistaminics, local anesthetics, and other amines as antiviral agents

Effect of chloroquine on the growth of animal viruses

Effects of chloroquine on viral infections: an old drug against today's diseases?

Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity

New insights into the antiviral effects of chloroquine

Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model

Mechanism of Borna disease virus entry into cells

Cytoplasmic trafficking of minute virus of mice: low-pH requirement, routing to late endosomes, and proteasome interaction

Endocytosis is a critical step in entry of subgroup B avian leukosis viruses

Examination of potential inhibitors of hepatitis A virus uncoating

Weak bases affect late stages of Mayaro virus replication cycle in vertebrate cells

Characterization of herpes simplex virus-containing organelles by subcellular fractionation: role for organelle acidification in assembly of infectious particles

Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Structural basis for human coronavirus attachment to sialic acid receptors

Identification of sialic acidbinding function for the Middle East respiratory syndrome coronavirus spike glycoprotein

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in vero cells

pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN

Acidotropic amines inhibit proteolytic processing of flavivirus prM protein

Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis

Use of chloroquine in viral diseases

Influenza A virus H5N1 entry into host cells is through clathrin-dependent endocytosis

Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors

Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling

Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferongamma production by peripheral blood mononuclear cells

Intracellular transport of class II MHC molecules directed by invariant chain

Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines

The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor

CpG-DNAspecific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation

New concepts in antimalarial use and mode of action in dermatology

Antimalarial ocular toxicity a critical appraisal

Disposition of chloroquine in man after single intravenous and oral doses

Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases

Bioavailability of hydroxychloroquine tablets in healthy volunteers

Antirheumatic Therapy: Actions and Outcomes

Antimalarials in rheumatic diseases

Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements

Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

Melanin: blackguard or red herring? Another look at chloroquine retinopathy

The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects

The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis

Five-compartment model of insulin kinetics and its use to investigate action of chloroquine in NIDDM

Distribution of chloroquine in ocular tissue of pigmented rat using matrix-assisted laser desorption/ionization imaging quadrupole time-of-flight tandem mass spectrometry

Antimalarial Drug II: Current Antimalarial and New Drug Developments

Ocular safety of hydroxychloroquine

Studies on the chemotherapy of the human malarias. VI. The physiological disposition, antimalaril activity, and toxicity of several derivatives of 4-aminoquinoline

Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine

Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials

Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate

Determination of the stereoisomers of hydroxychloroquine and its major metabolites in plasma and urine following a single oral administration of 44 racemic hydroxychloroquine

Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs

Relevance of drug-melanin interactions to ocular pharmacology and toxicology

Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis

Fulminant hepatic failure secondary to hydroxychloroquine

Fatal toxic epidermal necrolysis associated with hydroxychloroquine

Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia

Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine

The QT Interval in Patients with SARS-CoV-2 Infection Treated with

Reactions to chloroquine observed during the treatment of various dermatologic disorders

New insights into mechanisms of therapeutic effects of antimalarial agents in SLE

Antimalarials in the management of discoid and systemic lupus erythematosus

New insights into the antiviral effects of chloroquine

Ocular toxicity of hydroxychloroquine

The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: A reappraisal

Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy

Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus

Hydroxychloroquine-Induced Toxic Myopathy Causing Respiratory Failure

Hydroxychloroquine-Induced Myopathy

Severe hydroxychloroquine myopathy

Chloroquine-induced myopathy and neuropathy: progressive tetraparesis with areflexia that simulates a polyradiculoneuropathy

New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy-a report of 2 cases

Hydroxychloroquine-induced restrictive cardiomyopathy: Correlation between clinical, Echocardiographic and pathologic findings

Hydroxychloroquineinduced cardiomyopathy: a case report

Chloroquine induced urticaria: A newer adverse effect

Ototoxicity due to hydroxychloroquine: report of two cases

Hydroxychloroquine ototoxicity in a patient with rheumatoid arthritis

Chloroquine-induced recurrent psychosis

Hydroxychloroquine-induced seizure in a patient with systemic lupus erythematosus

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice

Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities

Screening of an FDA-approved compound library identifies four smallmolecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice

Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK

Effect of chloroquine on feline infectious peritonitis virus infection in vitro and in vivo

Induction of atypical autophagy by porcine hemagglutinating encephalomyelitis virus contributes to viral replication

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Effect of chloroquine on lysosomes and on growth of mouse hepatitis virus (MHV-3)

MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells

Alteration of the pH dependence of coronavirusinduced cell fusion: effect of mutations in the spike glycoprotein

Inhibition of human immunodeficiency virus infectivity by chloroquine

Antiretroviral treatment

Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea

The additive in vitro anti-HIV-1 effect of chloroquine, when combined with zidovudine and hydroxyurea

Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors

Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes

Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine

Chloroquine triggers Epstein-Barr virus replication through phosphorylation of KAP1/TRIM28 in Burkitt lymphoma cells

Cellular uptake of the tat protein from human immunodeficiency virus

Infectious cell entry mechanism of influenza virus

In vitro inhibition of human influenza A virus replication by chloroquine

Chloroquine is effective against influenza A virus in vitro but not in vivo

Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses

Mechanism of Uncoating of Influenza B Virus in MDCK Cells: Action of Chloroquine

Characterization of reemerging chikungunya virus

Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection

FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital Microcephaly in Mice

Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models

Repurposing of the anti-malaria drug chloroquine for Zika Virus treatment and prophylaxis

Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model

Lack of protection against ebola virus from chloroquine in mice and hamsters

A systematic screen of FDA-approved drugs for inhibitors of biological threat agents

Chloroquine interferes with dengue-2 virus replication in U937 cells

Chloroquine inhibits dengue virus type 2 replication in Vero cells but not in C6/36 cells

Effects of chloroquine and cytochalasin B on the infection of cells by Sindbis virus and vesicular stomatitis virus

Ammonium chloride and chloroquine inhibit rabies virus infection in neuroblastoma cells

Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy

Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds

Inhibition of duck hepatitis B virus infection by lysosomotropic agents

Early events in arenavirus replication are sensitive to lysosomotropic compounds

Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection

Japanese encephalitis virus enters rat neuroblastoma cells via a pH-dependent, dynamin and caveola-mediated endocytosis pathway

Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules

Chloroquine induces empty capsid formation during poliovirus eclipse

Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice

Chloroquine administration does not prevent Nipah virus infection and disease in ferrets

Chloroquine enhances replication of Semliki Forest virus and encephalomyocarditis virus in mice

Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial

A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults

On chikungunya acute infection and chloroquine treatment

Chloroquine use improves dengue-related symptoms

Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1

The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1

Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

COVID-19 patients with at least a six-day follow up: A pilot observational study

A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)

No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection

Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence

Indian Council for Medical Research. Recommendation for empiric use of hydroxychloroquine for prophylaxis of SARS-CoV-2 infection

The antiinflammatory and antiviral effects of hydroxychloroquine in two patients with acquired immunodeficiency syndrome and active inflammatory arthritis

Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1

The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1



